Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Companion Spine France Sas

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Companion Spine France Sas

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Companion Spine France Sas. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Dec 10, 2025 to Apr 1, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NQO appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240043, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: Immeuble Le Bridge 5, 5 Allee Des Acacias, Merignac, 33 700. Recorded on P240043/S001, decision dated Apr 1, 2026.

Changes described in PMA records

P240043/S001: DIAM Spinal Stabilization System

FDA’s recorded scope: Approval for a shelf-life extension from 1-year to 5-years for the DIAM Spinal Stabilization System. Based upon the information submitted, the PMA supplement is approved.

Apr 1, 2026 · Real-Time Process

P240043: DIAM Spinal Stabilization System

FDA’s recorded scope: The DIAM Spinal Stabilization System is indicated for skeletally mature patients that have moderate to severe primary low back pain (greater than leg pain) secondary to lumbar degenerative disc disease (DDD), at a single level from L2-L5 with current episode refractory to at least 6 months of non-operative care.Symptomatic disc disease is confirmed by patient history, physical examination, and radiographic evaluation with one or more of the following factors: Greater than 2mm of decreased disc height (average disc height) compared to the adjacent level Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule Non-extruded herniated nucleus pulposusThe DIAM device is implanted via a minimally invasive posterior approach.

Dec 10, 2025

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Companion Spine France SasPMA supplementApr 1, 2026FDA
Companion Spine France SasPMA approvalDec 10, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.